| Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up D Planchard, ST Popat, K Kerr, S Novello, EF Smit, C Faivre-Finn, TS Mok, ... Annals of Oncology 29, iv192-iv237, 2018 | 2382* | 2018 |
| Systematic review of microsatellite instability and colorectal cancer prognosis S Popat, R Hubner, RS Houlston Journal of clinical oncology 23 (3), 609-618, 2005 | 2141 | 2005 |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised … JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ... The lancet oncology 16 (2), 141-151, 2015 | 1746 | 2015 |
| Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ... Annals of Oncology 30 (8), 1321-1328, 2019 | 1021 | 2019 |
| Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up S Novello, F Barlesi, R Califano, T Cufer, S Ekman, MG Levra, K Kerr, ... Annals of Oncology 27, v1-v27, 2016 | 987 | 2016 |
| Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, JS Lee, MJ Hochmair, ... New England Journal of Medicine 379 (21), 2027-2039, 2018 | 869 | 2018 |
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ... The Lancet 397 (10272), 375-386, 2021 | 804 | 2021 |
| Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Reck, S Popat, N Reinmuth, D De Ruysscher, KM Kerr, S Peters Annals of oncology 25, iii27-iii39, 2014 | 790 | 2014 |
| Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up M Früh, D De Ruysscher, S Popat, L Crinò, S Peters, E Felip Annals of oncology 24, vi99-vi105, 2013 | 695 | 2013 |
| Guidelines on the radical management of patients with lung cancer E Lim, D Baldwin, M Beckles, J Duffy, J Entwisle, C Faivre-Finn, K Kerr, ... Thorax 65 (Suppl 3), iii1-iii27, 2010 | 669 | 2010 |
| Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis S Popat, A Matakidou, RS Houlston Journal of Clinical Oncology 22 (3), 529-536, 2004 | 589 | 2004 |
| Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial K Nakagawa, EB Garon, T Seto, M Nishio, SP Aix, L Paz-Ares, CH Chiu, ... The Lancet Oncology 20 (12), 1655-1669, 2019 | 511 | 2019 |
| First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases M Schuler, YL Wu, V Hirsh, K O’Byrne, N Yamamoto, T Mok, S Popat, ... Journal of Thoracic Oncology 11 (3), 380-390, 2016 | 358 | 2016 |
| Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry O Gautschi, J Milia, T Filleron, J Wolf, DP Carbone, D Owen, R Camidge, ... Journal of Clinical Oncology 35 (13), 1403, 2017 | 346 | 2017 |
| Platinum-based chemotherapy in triple-negative breast cancer B Sirohi, M Arnedos, S Popat, S Ashley, A Nerurkar, G Walsh, S Johnston, ... Annals of oncology 19 (11), 1847-1852, 2008 | 346 | 2008 |
| Novel insights into mesothelioma biology and implications for therapy TA Yap, JG Aerts, S Popat, DA Fennell Nature Reviews Cancer 17 (8), 475-488, 2017 | 327 | 2017 |
| Brigatinib versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer: second interim analysis of the phase III ALTA-1L trial DR Camidge, HR Kim, MJ Ahn, JCH Yang, JY Han, MJ Hochmair, KH Lee, ... Journal of Clinical Oncology 38 (31), 3592-3603, 2020 | 291 | 2020 |
| Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and … AG Nicholson, D Gonzalez, P Shah, MJ Pynegar, M Deshmukh, A Rice, ... Journal of Thoracic Oncology 5 (4), 436-441, 2010 | 265 | 2010 |
| A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis S Popat, RS Houlston European journal of cancer 41 (14), 2060-2070, 2005 | 259 | 2005 |
| High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial A Pearson, E Smyth, IS Babina, MT Herrera-Abreu, N Tarazona, C Peckitt, ... Cancer discovery 6 (8), 838-851, 2016 | 256 | 2016 |
solange petersVerified email at chuv.ch
